Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q1 2026 Earnings Presentation
14 slides from Tarsus Pharmaceuticals's earnings presentation, May 6, 2026
Slide 1: Building the Future of Eye Care
Building the Future of Eye Care Q1 2026 Financial Results May 2026 Vivian, an XDEMVY patient.
Slide 2: Today's Speakers
World-Class Leadership Team With Proven Track Record of Success: Today’s Speakers Bobby Azamian, MD, PhD Aziz Mottiwala Jeff Farrow CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including 2026 financial guidance, market size, acceptanc
Slide 4: XDEMVY Is Just Getting Started
XDEMVY® Is Just Getting Started $2B+ $2B+ Peak Sales Potential Peak Sales Potential Deepening High-Impact DTC Evidence Utilization Campaign Generation Nearly half of target ECPs DTC campaign driving increasing New data broadening how ECPs prescribing weekly with KAL team returns, with impactful new
Slide 5: TP-05: Potential to Fundamentally Shift the Lyme Disease Paradigm From Management to Prevention
TP-05: Potential to Fundamentally Shift the Lyme Disease Paradigm From Management to Prevention Initiated Calliope • ~700 participants in endemic areas of the U.S. • Designed to kill ticks before transmission occurs Phase 2 Trial • Expected to be completed within one single tick season with data exp
Slide 6: TP-04: Potential to Become the First-Ever FDA-Approved Medicine for Ocular Rosacea
TP-04: Potential to Become the First-Ever FDA-Approved Medicine for Ocular Rosacea • Vehicle-controlled 16-week trial Ongoing KORE • Newly developed endpoints with grading scales Phase 2 Trial • Data expected in 1H 2027 FDA-Endorsed Clear Objective Endpoints Mechanism of Action Telangiectasia Improv
Slide 7: Depth, Demand and Data Powering XDEMVY's Growth
Depth, Demand and Data Powering XDEMVY’s Growth Increasing Depth of Prescribing Nearly half of target ECPs prescribing on a weekly basis1 Expanding the Patient Funnel DTC campaign driving more patients into ECP offices Generating Evidence to Broaden Screening Giving ECPs more reasons to look and tre
Slide 8: DTC Driving Patients Into ECP Offices and ROI Exceeding Initial Expectations
DTC Driving Patients Into ECP Offices and ROI Exceeding Initial Expectations ~40% Positive and growing ROI on DTC campaign QoQ increase in high-value actions on XDEMVY.com1 • MORE TO COME: New high-impact creative and disease- state messaging planned to launch in coming weeks and expected to drive e
Slide 9: Compelling New Evidence Gives ECPs More Reasons to Screen, Diagnose and Treat Demodex Blepharitis
Compelling New Evidence Gives ECPs More Reasons to Screen, Diagnose and Treat Demodex Blepharitis 71% Showed Signs of Reinforces XDEMVY as Demodex Blepharitis Could Underlying DB the Standard of Care Increase Infection Risk Emphasizing the importance of The only treatment with proven, Strengthening
Slide 10: XDEMVY Growth Engine Driving $2B+ Peak Sales Potential
XDEMVY® Growth Engine Driving $2B+ $2B+ Peak Sales Potential Peak Sales Potential Deepening Growing High-Impact DTC Evidence Utilization Retreatment Campaign Generation Nearly half of target ECPs Retreatment trending in Driving increasing returns, New data broadening how prescribing weekly; mid-teen
Slide 11: Continued Growth in Q1 With Clear Line of Sight to $2B+ Potential
Continued Growth in Q1 With Clear Line of Sight to $2B+ Potential $145.4 Q1 2026 Reaffirm 2026 Annual Guidance XDEMVY Net Sales +85% Q1 2026 YoY Net $388.7mm Cash & Cash Sales Growth Equivalents 11 | © Tarsus Pharmaceuticals | For Investor Purposes Only Note: U.S. dollars in millions unless otherwis
Slide 12: Advancing Pipeline with Proven Category-Creating Playbook
Advancing Pipeline with Proven Category-Creating Playbook Global and Pipeline Lyme Prevention (TP-05)1 Ocular Rosacea (TP-04)1 Opportunities Initiated Phase 2 Calliope trial; Ongoing Phase 2 KORE trial; On track for global topline data expected 1H 2027 topline data expected 1H 2027 expansion and goa
Slide 13: Proven Execution with Clear Catalysts Expected Ahead
Proven Execution with Clear Catalysts Expected Ahead XDEMVY®: Clear Plans to Transform Delivering Continued Path to $2B+ Sales Standards of Care Value Creation Potential *$2B+ Ocular Rosacea $670- $700mm $451mm $180mm Accelerate progress by potentially 2024A 2025A 2026E 2027+ adding 1-2 new programs
Slide 14: Thank You!
Thank You! 14 | © Tarsus Pharmaceuticals | For Investor Purposes Only Diamond, an XDEMVY patient.
Tarsus Pharmaceuticals — Q1 2026 Earnings Presentation on 6ix